These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25756405)

  • 1. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
    Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
    Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary.
    Taniguchi F; Itamochi H; Harada T; Terakawa N
    Int J Gynecol Cancer; 2013 Jun; 23(5):791-6. PubMed ID: 23640291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.
    Czaplinska D; Mieczkowski K; Supernat A; Skladanowski AC; Kordek R; Biernat W; Zaczek AJ; Romanska HM; Sadej R
    Tumour Biol; 2016 Oct; 37(10):13721-13731. PubMed ID: 27476168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
    Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
    J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
    Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
    Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
    Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
    Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.
    Itamochi H; Oumi N; Oishi T; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
    Int J Clin Oncol; 2015 Oct; 20(5):967-73. PubMed ID: 25744580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
    Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
    Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
    Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
    Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3.
    Min KW; Park MH; Hong SR; Lee H; Kwon SY; Hong SH; Joo HJ; Park IA; An HJ; Suh KS; Oh HK; Yoo CW; Kim MJ; Chang HK; Jun SY; Yoon HK; Chang ED; Kim DW; Kim I;
    Int J Gynecol Pathol; 2013 Jan; 32(1):3-14. PubMed ID: 23202783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
    Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
    Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear‑cell carcinoma cells.
    Kawai Y; Shibata K; Sakata J; Suzuki S; Utsumi F; Niimi K; Sekiya R; Senga T; Kikkawa F; Kajiyama H
    Oncol Rep; 2018 Jul; 40(1):195-205. PubMed ID: 29749467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
    Hirata Y; Murai N; Yanaihara N; Saito M; Saito M; Urashima M; Murakami Y; Matsufuji S; Okamoto A
    BMC Cancer; 2014 Nov; 14():799. PubMed ID: 25366985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
    Hazama Y; Moriya T; Sugihara M; Sano R; Shiota M; Nakamura T; Shimoya K
    Int J Gynecol Pathol; 2018 Nov; 37(6):516-524. PubMed ID: 29019869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
    Abe A; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
    Hum Pathol; 2013 Feb; 44(2):199-207. PubMed ID: 22955107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.
    Zhu DY; Guo QS; Li YL; Cui B; Guo J; Liu JX; Li P
    World J Gastroenterol; 2014 Dec; 20(48):18306-15. PubMed ID: 25561797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pure and mixed-type clear cell carcinoma of the ovary: a clinicopathological analysis of 341 Chinese patients.
    Ye S; You Y; Yang J; Cao D; Bai H; Huang H; Wu M; Chen J; Lang J; Shen K
    Int J Gynecol Cancer; 2014 Nov; 24(9):1590-6. PubMed ID: 25254564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
    Takaya A; Peng WX; Ishino K; Kudo M; Yamamoto T; Wada R; Takeshita T; Naito Z
    Int J Oncol; 2015 Apr; 46(4):1573-81. PubMed ID: 25633807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.